Biomarkers for Heart Failure Prediction and Prevention

Heart failure (HF) is a global pandemic affecting over 64 million people worldwide. Its prevalence is on an upward trajectory, with associated increasing healthcare expenditure. Organizations including the American College of Cardiology (ACC) and the American Heart Association (AHA) have identified...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of cardiovascular development and disease Ročník 10; číslo 12; s. 488
Hlavní autoři: Kotta, Prasanti Alekhya, Nambi, Vijay, Bozkurt, Biykem
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 01.12.2023
Témata:
Associations, institutions, etc
Atherosclerosis
Biological markers
Biomarkers
Canada
Cardiovascular disease
Development and progression
Disease prevention
Epidemics
Health risks
Heart failure
Medical care, Cost of
Medical prognosis
Peptides
prediction
Prevention
Risk factors
screening
Societies
Stage B heart failure
Type 2 diabetes
Womens health
Canada
heart failure
pre-heart failure
screening
biomarkers
prediction
Stage B heart failure
prevention
ISSN:2308-3425, 2308-3425
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Heart failure (HF) is a global pandemic affecting over 64 million people worldwide. Its prevalence is on an upward trajectory, with associated increasing healthcare expenditure. Organizations including the American College of Cardiology (ACC) and the American Heart Association (AHA) have identified HF prevention as an important focus. Recently, the ACC/AHA/Heart Failure Society of America (HFSA) Guidelines on heart failure were updated with a new Class IIa, Level of Evidence B recommendation for biomarker-based screening in patients at risk of developing heart failure. In this review, we evaluate the studies that have assessed the various roles and contributions of biomarkers in the prediction and prevention of heart failure. We examined studies that have utilized biomarkers to detect cardiac dysfunction or abnormality for HF risk prediction and screening before patients develop clinical signs and symptoms of HF. We also included studies with biomarkers on prognostication and risk prediction over and above existing HF risk prediction models and studies that address the utility of changes in biomarkers over time for HF risk. We discuss studies of biomarkers to guide management and assess the efficacy of prevention strategies and multi-biomarker and multimodality approaches to improve risk prediction.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2308-3425
2308-3425
DOI:10.3390/jcdd10120488